[Development of Therapies Targeting Non-G12C KRAS Mutations (Focusing on G12D and Pan-RAS)].

Abstract excerpt

Sotorasib and adagrasib, which are KRAS G12C inhibitors, have shown favorable clinical results mainly in non-small cell lung cancer (NSCLC) and have already been introduced into clinical practice. However, for patients with non-G12C mutations that account for the majority, such as G12D, G12V, and G13D, effective targeted therapies have still not been established. Setidegrasib (ASP3082) is a first-in-class...

Topics

Join the communities discussing this publication.

• Antineoplastic Agents
• Clinical Trials as Topic
• HRAS gene
• NRAS gene
• Lung Neoplasms